Breaking Down AngioDynamics, Inc. (ANGO) Financial Health: Key Insights for Investors

Are you keeping a close watch on AngioDynamics, Inc. (ANGO) and wondering about its financial stability? With a market cap of $656.47 million as of today, it's crucial to understand the key metrics that drive its financial health. Did you know that AngioDynamics reported a revenue of $356.4 million for the fiscal year 2024? But revenue isn't the whole story. How does their gross profit of $189.5 million and operating income of $8.9 million stack up against their debt of $147.8 million? Dive in to explore these figures and more, gaining insights into whether AngioDynamics presents a promising opportunity or a potential risk for investors.

AngioDynamics, Inc. (ANGO) Revenue Analysis

Analyzing AngioDynamics, Inc.'s revenue streams provides critical insights into the company's financial health and business strategy. A detailed look at revenue sources, growth rates, and segment contributions helps investors understand where the company is succeeding and where there may be challenges.

AngioDynamics primarily generates revenue from the sale of medical devices used in minimally invasive procedures. These devices are categorized into several key product lines, serving areas such as:

• Peripheral Vascular: Devices used in the treatment of peripheral artery disease and other vascular conditions.
• Angiographic Products: Products utilized in diagnostic and therapeutic angiography.
• Oncology: Devices for tumor ablation and other cancer treatments.
• Vascular Access: Products that provide access to the bloodstream for medication delivery, fluid management, and other purposes.

For instance, during the 2024 fiscal year, AngioDynamics reported total net sales of $336.7 million. This figure reflects the company's ability to generate revenue across its diverse product lines and geographic markets. Understanding the specific contributions of each segment is essential for assessing the company's overall performance and growth potential.

A closer examination of the company's performance reveals the nuances within its revenue streams. For example, let's consider the year-over-year revenue growth rates, which provide insights into the company's momentum and market position. Here’s a summary of AngioDynamics' revenue performance:

• In Q3 2024, AngioDynamics reported net sales of $84.5 million, which was slightly below the $85.6 million reported in Q3 2023.
• For the first three quarters of fiscal 2024, the company's net sales totaled $253.8 million, compared to $257.8 million in the prior year.

The following table provides a detailed breakdown of net sales by product category for Q3 2024 and the first three quarters of fiscal 2024, compared to the corresponding periods in fiscal 2023 (in thousands):

Furthermore, geographic performance plays a crucial role in AngioDynamics' revenue composition. While specific regional breakdowns require detailed financial reports, it is generally understood that the company operates both domestically within the United States and internationally. The balance between these markets can influence overall revenue stability and growth prospects.

To gain a deeper understanding of investor sentiment and market dynamics surrounding AngioDynamics, Inc. (ANGO), explore this insightful profile: Exploring AngioDynamics, Inc. (ANGO) Investor Profile: Who’s Buying and Why?

AngioDynamics, Inc. (ANGO) Profitability Metrics

Analyzing AngioDynamics, Inc.'s (ANGO) profitability involves examining several key metrics that provide insights into its financial health and operational efficiency. These include gross profit, operating profit, and net profit margins, as well as trends in these metrics over time.

For the fiscal year 2024, which ended on May 31, 2024, AngioDynamics reported the following:

• Pro Forma Net Sales: $270.7 million, a 5.3% increase compared to the prior year.
• Med Tech Net Sales: $106.0 million, a 10.1% increase from the prior year.
• Med Device Net Sales: $164.8 million, a 2.4% increase from the prior year.
• GAAP Gross Margin: 50.9%.
• Pro Forma Gross Margin: 53.8%, a decrease of 110 basis points from 54.9% a year ago.
• GAAP Net Loss: $184.3 million, or a loss per share of $4.59.
• Adjusted Loss Per Share: $0.45.

In the third quarter of fiscal year 2025, which ended February 28, 2025, AngioDynamics reported:

• Pro Forma Net Sales: $72.0 million, up 9.2% year-over-year.
• MedTech Sales: $31.3 million, growing 22.2%.
• MedDevice Sales: $40.7 million, up 0.9%.
• GAAP Gross Margin: 54.0%, a 290 basis points increase compared to the third quarter of fiscal 2024.
• GAAP Net Loss: $4.4 million, or a loss per share of $0.11.
• Adjusted EBITDA: $1.3 million.

The company's gross margin trends show some fluctuation. For instance, the gross margin for the Med Tech business in the third quarter of fiscal 2025 was 62.5%, an increase of 100 basis points from the third quarter of fiscal 2024. The gross margin for the Med Device business in the same period was 47.4%, an increase of 300 basis points compared to the third quarter of fiscal 2024.

In the fourth quarter of fiscal year 2024, the GAAP gross margin was 54.3%, which was flat compared to the fourth quarter of fiscal year 2023, but up 320 basis points sequentially from 51.1% in the third quarter.

The company's operating margin has been negative. According to a report as of March 2025, the trailing twelve months (TTM) operating margin was -82.86%. The operating margin at the end of 2023 was -16.07%.

AngioDynamics has been implementing strategic initiatives to improve its cost management and operational efficiency. These include:

• Transitioning manufacturing operations to a fully outsourced model to drive efficiencies and cost savings.
• Optimizing the Med Device business through divestitures and discontinuation of certain product lines.

These actions are aimed at streamlining operations and focusing on high-growth areas within the Med Tech segment.

Here is a summary of AngioDynamics' financial guidance for fiscal year 2025:

• Net sales are expected to be in the range of $285 to $288 million, representing growth of between 5.3% – 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
• Med Tech net sales are expected to grow in the range of 14% to 16%.
• Med Device net sales are expected to be flat.
• Gross margin is expected to be approximately 53% to 54%.
• Adjusted EBITDA is expected to be in the range of $4.0 to $5.0 million, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal 2024.
• Adjusted loss per share is expected to be in the range of $0.31 to $0.34, an improvement from the previous guidance of a loss of $0.34 to $0.38.

For more insights into the company's mission, vision, and core values, you can refer to Mission Statement, Vision, & Core Values of AngioDynamics, Inc. (ANGO).

AngioDynamics, Inc. (ANGO) Debt vs. Equity Structure

AngioDynamics, Inc. (ANGO) employs a mix of debt and equity to fuel its growth initiatives. Understanding the levels and types of debt the company carries, along with its debt-to-equity ratio, provides insights into its financial leverage and risk profile. Here's a breakdown of AngioDynamics' debt and equity structure:

As of the third quarter of fiscal year 2024, AngioDynamics, Inc. (ANGO) reported the following debt situation:

• Total debt: $25.0 million.

AngioDynamics, Inc. (ANGO) has strategically managed its debt, as highlighted in their financial reports. Recent activities include:

• On May 6, 2024, AngioDynamics, Inc. (ANGO) announced the prepayment of its term loan, resulting in $25 million being outstanding under its revolving credit facility. This move showcases active management of their debt obligations.

The company's approach to balancing debt and equity is crucial for sustaining growth while maintaining financial stability. The debt-to-equity ratio is a key metric in assessing this balance. However, specific details on AngioDynamics' debt-to-equity ratio and industry comparisons require updated data.

Factors influencing AngioDynamics' financing decisions include market conditions, investment opportunities, and strategic priorities. The company's ability to secure favorable credit ratings and refinance debt on advantageous terms further supports its financial flexibility.

For further insights into AngioDynamics, Inc. (ANGO) financial health, read more here: Breaking Down AngioDynamics, Inc. (ANGO) Financial Health: Key Insights for Investors

AngioDynamics, Inc. (ANGO) Liquidity and Solvency

Assessing AngioDynamics, Inc.'s financial health requires a close look at its liquidity and solvency positions. Liquidity refers to the company's ability to meet its short-term obligations, while solvency indicates its ability to meet long-term obligations.

Key metrics to consider include current and quick ratios, working capital trends, and cash flow statements.

Here's a breakdown:

Liquidity Positions: Current and Quick Ratios

The current and quick ratios are essential indicators of a company's ability to cover its short-term liabilities with its short-term assets. A higher ratio generally indicates better liquidity.

• Current Ratio: This ratio measures a company's ability to pay off its current liabilities with its current assets. It is calculated by dividing current assets by current liabilities.
• Quick Ratio: Also known as the acid-test ratio, this is a more conservative measure than the current ratio, as it excludes inventories from current assets. It is calculated as (Current Assets - Inventory) / Current Liabilities.

Analysis of Working Capital Trends

Working capital, calculated as current assets minus current liabilities, is a measure of a company's short-term financial health. Monitoring the trends in working capital can provide insights into whether a company's liquidity position is improving or deteriorating.

Cash Flow Statements Overview

Cash flow statements provide a detailed look at all the cash inflows and outflows a company experiences during a reporting period, categorized into operating, investing, and financing activities.

• Operating Cash Flow: Cash generated from the company's core business activities. A positive and increasing trend is generally a good sign.
• Investing Cash Flow: Cash flow related to the purchase and sale of long-term assets.
• Financing Cash Flow: Cash flow related to debt, equity, and dividends.

Potential Liquidity Concerns or Strengths

Investors should watch for any red flags in these metrics, such as:

• A declining current or quick ratio, which may indicate deteriorating liquidity.
• Negative operating cash flow, which suggests the company is struggling to generate cash from its core operations.
• A significant increase in short-term debt, which could strain the company's ability to meet its obligations.

Conversely, strengths might include:

• A consistently high current or quick ratio.
• Strong positive operating cash flow.
• Effective management of working capital.

By analyzing these factors, investors can gain a better understanding of AngioDynamics, Inc.'s financial health and make more informed investment decisions.

More insights about AngioDynamics, Inc. (ANGO) can be found here: Mission Statement, Vision, & Core Values of AngioDynamics, Inc. (ANGO).

AngioDynamics, Inc. (ANGO) Valuation Analysis

Determining whether AngioDynamics, Inc. (ANGO) is overvalued or undervalued requires a multifaceted approach, incorporating key financial ratios, stock performance analysis, and analyst sentiment. Let's delve into these aspects to provide a clearer picture for investors. For additional insights, you might find this resource helpful: Breaking Down AngioDynamics, Inc. (ANGO) Financial Health: Key Insights for Investors.

To assess AngioDynamics, Inc.'s (ANGO) valuation, several key ratios are essential:

• Price-to-Earnings (P/E) Ratio: This ratio compares the company’s stock price to its earnings per share (EPS), indicating how much investors are willing to pay for each dollar of earnings.
• Price-to-Book (P/B) Ratio: This ratio compares the company’s market capitalization to its book value, helping to identify if the stock is trading at a premium or discount to its net asset value.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: This ratio compares the company’s enterprise value (total market value plus debt, minus cash) to its earnings before interest, taxes, depreciation, and amortization (EBITDA), providing a valuation measure that accounts for debt levels.

Analyzing AngioDynamics, Inc.'s (ANGO) stock price trends over the past year can provide valuable context. Significant price fluctuations, upward trends, or downward spirals can reflect market sentiment and company performance. As of April 2025, the stock's behavior over the preceding 12 months would be critical in gauging investor confidence and potential future movements.

As of the latest data in 2024 fiscal year, AngioDynamics, Inc. (ANGO) does not offer a dividend. Therefore, dividend yield and payout ratios are not applicable in this valuation analysis.

Here's a look at how analysts are currently rating AngioDynamics, Inc. (ANGO):

Keep in mind that analyst ratings can vary and should be considered alongside other valuation metrics and your own research. Some analysts may have a buy recommendation, suggesting they believe the stock is undervalued and has potential for growth. Others may suggest a hold, indicating that the stock is fairly valued or that they are uncertain about its near-term prospects. Conversely, a sell rating implies that analysts believe the stock is overvalued and may underperform.

AngioDynamics, Inc. (ANGO) Risk Factors

AngioDynamics, Inc. (ANGO) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges, external market pressures, and broader industry-specific concerns. Understanding these factors is crucial for investors assessing the company's stability and growth potential. These risks are often detailed in their filings with the Securities and Exchange Commission (SEC), including their annual reports (10-K) and quarterly reports (10-Q).

Here's an overview of key risks facing AngioDynamics, Inc. (ANGO):

• Industry Competition: The medical device industry is highly competitive. AngioDynamics, Inc. (ANGO) competes with numerous companies, some of which have greater financial, technical, and marketing resources. Increased competition could lead to price reductions, reduced sales volumes, and loss of market share.
• Regulatory Changes: The medical device industry is heavily regulated by government agencies such as the U.S. Food and Drug Administration (FDA) and their international counterparts. Changes in regulations, including those related to product approvals, manufacturing, and marketing, could increase compliance costs, delay product launches, and adversely affect profitability.
• Market Conditions: Economic downturns, changes in healthcare spending, and shifts in medical practices can impact demand for AngioDynamics, Inc.'s (ANGO) products. For instance, reduced hospital budgets or a decline in elective procedures could lower sales.
• Product Liability: As a medical device manufacturer, AngioDynamics, Inc. (ANGO) faces the risk of product liability claims if its devices cause or are alleged to have caused injury. These claims can be costly to defend and could result in significant financial liabilities.
• Intellectual Property: The company’s success depends partly on its ability to protect its intellectual property. Challenges to or infringement of its patents and other intellectual property rights could harm its competitive position.

Operational, financial, and strategic risks are often highlighted in AngioDynamics, Inc.'s (ANGO) earnings reports and filings. These may include:

• Supply Chain Disruptions: Disruptions in the supply chain, whether due to geopolitical events, natural disasters, or other factors, can affect the company’s ability to manufacture and distribute its products.
• Cybersecurity Threats: The increasing reliance on digital technologies makes AngioDynamics, Inc. (ANGO) vulnerable to cybersecurity threats, which could compromise sensitive data, disrupt operations, and damage its reputation.
• Acquisition and Integration Risks: AngioDynamics, Inc. (ANGO) may pursue acquisitions to expand its product offerings or market presence. However, integrating acquired businesses can be complex and may not always be successful.

Mitigation strategies or plans, if available, might include:

• Diversification: Diversifying its product portfolio and geographic markets can reduce AngioDynamics, Inc.'s (ANGO) reliance on any single product or market.
• Compliance Programs: Implementing robust compliance programs to ensure adherence to regulatory requirements can minimize the risk of penalties and legal issues.
• Risk Management: Employing comprehensive risk management practices to identify, assess, and mitigate potential risks can enhance the company’s resilience.

For more insights into AngioDynamics, Inc.'s (ANGO) financial health, you can explore this resource: Breaking Down AngioDynamics, Inc. (ANGO) Financial Health: Key Insights for Investors

AngioDynamics, Inc. (ANGO) Growth Opportunities

AngioDynamics, Inc. (ANGO) faces a dynamic future shaped by several growth catalysts. These include strategic product innovations, targeted market expansions, and potential acquisitions that could significantly enhance its market position and financial performance.

Key growth drivers for AngioDynamics, Inc. (ANGO) are:

• Product Innovations: AngioDynamics, Inc. (ANGO) invests in research and development to introduce new and improved products.
• Market Expansion: Expanding into new geographic regions and customer segments can drive revenue growth.
• Acquisitions: Strategic acquisitions can broaden AngioDynamics, Inc. (ANGO)'s product portfolio and market reach.

While specific future revenue growth projections and earnings estimates for AngioDynamics, Inc. (ANGO) are subject to market conditions and company performance, analysts generally provide forecasts based on current trends and company strategies. For instance, in the third quarter of fiscal year 2024, AngioDynamics, Inc. (ANGO) reported net sales of $83.8 million, a 0.7% increase compared to the prior year. This indicates a steady, albeit modest, growth trajectory.

Strategic initiatives that may drive future growth include:

• Partnerships: Collaborations with other companies can provide access to new technologies and markets.
• New Product Launches: Introducing innovative products can attract new customers and increase sales.
• Geographic Expansion: Expanding into new regions can tap into new sources of revenue.

AngioDynamics, Inc. (ANGO)'s competitive advantages that position the company for growth are:

• Proprietary Technology: Unique technology that differentiates AngioDynamics, Inc. (ANGO)'s products from competitors.
• Strong Customer Relationships: Established relationships with healthcare providers and distributors.
• Experienced Management Team: A capable leadership team with a track record of success.

A SWOT analysis further illuminates AngioDynamics, Inc. (ANGO)'s strategic positioning:

For further insights into the company's values and long-term goals, refer to Mission Statement, Vision, & Core Values of AngioDynamics, Inc. (ANGO).